{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:54:18Z","timestamp":1786964058061,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1111\/j.1538-7836.2005.01418.x","type":"journal-article","created":{"date-parts":[[2005,8,8]],"date-time":"2005-08-08T04:34:38Z","timestamp":1123475678000},"page":"1577-1589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Therapeutic approaches in arterial thrombosis"],"prefix":"10.1016","volume":"3","author":[{"given":"D.R.","family":"PHILLIPS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.","family":"CONLEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"SINHA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"ANDRE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0010","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.292.20.2495","article-title":"Trends in cardiovascular complications of diabetes","volume":"292","author":"Fox","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0015","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20102. ISIS\u20102 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","author":"Fox","year":"1988","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy \u2013 I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration","volume":"308","author":"Fox","year":"1994","journal-title":"Br Med J"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta\u2010analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Fox","year":"2002","journal-title":"Br Med J"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0030","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/13543776.11.11.1663","article-title":"Recent developments of thromboxane modulators","volume":"11","author":"Dogne","year":"2001","journal-title":"Expert Opin Ther Patents"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14728214.8.2.349","article-title":"Advances in antiplatelet therapy","volume":"8","author":"Jneid","year":"2003","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1358863X9600100210","article-title":"The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study","volume":"1","author":"Janzon","year":"1996","journal-title":"Vasc Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Janzon","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0050","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long\u2010term therapy in patients undergoing percutaneous coronary intervention: the PCI\u2010CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0060","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.100.4.437","article-title":"Platelet glycoprotein IIb\/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use","volume":"100","author":"Scarborough","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0070","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1067\/mhj.2000.110458","article-title":"Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention","volume":"140","author":"O'Shea","year":"2000","journal-title":"Am Heart J"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0075","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low\u2010dose heparin during percutaneous coronary revascularization. The EPILOG Investigators","volume":"336","author":"O'Shea","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0080","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high\u2010risk coronary angioplasty. The EPIC Investigation","volume":"330","author":"O'Shea","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low\u2010molecular\u2010weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non\u2010Q\u2010Wave Coronary Events Study Group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0090","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2010Q\u2010wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0095","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta\u2010analysis of 4 randomized double\u2010blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic\u2010drug regimens after coronary\u2010artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0105","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","article-title":"Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study","volume":"98","author":"Bertrand","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrd985","article-title":"Scientific and therapeutic advances in antiplatelet therapy","volume":"2","author":"Bhatt","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0735-1097(00)00817-2","article-title":"Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy","volume":"36","author":"Moshfegh","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0120","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1161\/01.CIR.0000093279.36628.12","article-title":"Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis","volume":"108","author":"Andre","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/jpet.103.059873","article-title":"Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel","volume":"309","author":"Lorrain","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0130","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1182\/blood-2003-03-0850","article-title":"Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain","volume":"102","author":"Ni","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0135","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.95.14.8070","article-title":"Coactivation of two different G protein\u2010coupled receptors is essential for ADP\u2010induced platelet aggregation","volume":"95","author":"Jin","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0140","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/nm943","article-title":"G13 is an essential mediator of platelet activation in hemostasis and thrombosis","volume":"9","author":"Moers","year":"2003","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0145","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V98.12.3340","article-title":"Blockade of adenosine diphosphate receptors P2Y12 and P2Y1 is required to inhibit platelet aggregation in whole blood under flow","volume":"98","author":"Turner","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0150","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high\u2010risk patients with non\u2010ST\u2010segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0160","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0165","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin\u2010resistant thromboxane synthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0170","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"Zimmermann","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0175","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella\u2010Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/14622416.2.4.341","article-title":"Common variations in platelet glycoproteins: pharmacogenomic implications","volume":"2","author":"Topol","year":"2001","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0185","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1160\/TH04-02-0105","article-title":"Pharmacokinetics of clopidogrel after administration of a high loading dose","volume":"92","author":"Taubert","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0195","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","article-title":"Prevalence of clopidogrel non\u2010responders among patients with stable angina pectoris scheduled for elective coronary stent placement","volume":"89","author":"Muller","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0200","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ehj.2004.07.036","article-title":"High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability","volume":"25","author":"Angiolillo","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0205","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0210","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2010drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non\u2010ST\u2010segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial","volume":"292","author":"Blazing","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0225","first-page":"1474","article-title":"The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators","volume":"29","author":"Blazing","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0230","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE\u20102 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0235","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMoa035162","article-title":"Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement","volume":"349","author":"Francis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0240","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non\u2010valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1527-3466.2003.tb00124.x","article-title":"RWJ\u201058259: a selective antagonist of protease activated receptor\u20101","volume":"21","author":"Damiano","year":"2003","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0250","series-title":"Medi 85. 227 ACS National Meeting","article-title":"Discovery and optimization of potent orally active small molecular thrombin receptor (PAR\u20101) antagonits","author":"Kawahara","year":"2004"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","article-title":"Open multicentre study of the P2T receptor antagonist AR\u2010C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes","volume":"85","author":"Storey","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0260","series-title":"From ATP to AZD6140: Design of an Orally Active P2Y12 Receptor Antagonist for the Treatment of Thrombosis","author":"Springthorpe","year":"2003"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0265","first-page":"223","article-title":"Best of the ESC 2004","volume":"5","author":"Springthorpe","year":"2004","journal-title":"Rev Cardiovasc Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0270","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0275","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","article-title":"Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs","volume":"107","author":"Foster","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0280","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8399","article-title":"Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor\u2010null mice","volume":"104","author":"Leon","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0285","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/13522","article-title":"Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1\u2010deficient mice","volume":"5","author":"Fabre","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0290","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries","volume":"112","author":"Andre","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0295","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1021\/jm030127+","article-title":"2\u2010Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists","volume":"46","author":"Kim","year":"2003","journal-title":"J Med Chem"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0300","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.bmc.2003.12.041","article-title":"Synthesis and biological activity of 2\u2010alkylated deoxyadenosine bisphosphate derivatives as P2Y(1) receptor antagonists","volume":"12","author":"Mathieu","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0305","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/44599","article-title":"Integrin cytoplasmic tyrosine motif is required for outside\u2010in alphaIIbbeta3 signalling and platelet function","volume":"401","author":"Law","year":"1999","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0310","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet\u2010derived CD40L: the switch\u2010hitting player of cardiovascular disease","volume":"106","author":"Andre","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0315","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3 integrin\u2010dependent mechanism","volume":"8","author":"Andre","year":"2002","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0320","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00062752-200309000-00006","article-title":"The platelet CD40L\/GP IIb\u2010IIIa axis in atherothrombotic disease","volume":"10","author":"Prasad","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/84667","article-title":"Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis","volume":"7","author":"Angelillo\u2010Scherrer","year":"2001","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1172\/JCI22079","article-title":"Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy","volume":"115","author":"Angelillo\u2010Scherrer","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0335","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1073\/pnas.142053899","article-title":"Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell\u2010to\u2010cell contact has occurred","volume":"99","author":"Prevost","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0340","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2003-03-0889","article-title":"Platelet receptor interplay regulates collagen\u2010induced thrombus formation in flowing human blood","volume":"103","author":"Siljander","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0345","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V88.6.2081.bloodjournal8862081","article-title":"Analysis of platelet adhesion to a collagen\u2010coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion","volume":"88","author":"Moroi","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0350","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1160\/TH04-05-0312","article-title":"Defective collagen\u2010induced platelet activation in two patients with malignant haemopathies is related to a defect in the GPVI\u2010coupled signalling pathway","volume":"93","author":"Bellucci","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0355","doi-asserted-by":"crossref","first-page":"10912","DOI":"10.1074\/jbc.275.15.10912","article-title":"A new platelet receptor specific to type III collagen. Type III collagen\u2010binding protein","volume":"275","author":"Monnet","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0360","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1172\/JCI114318","article-title":"A patient with platelets deficient in glycoprotein VI that lack both collagen\u2010induced aggregation and adhesion","volume":"84","author":"Moroi","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0365","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2141.1995.tb08900.x","article-title":"Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency","volume":"89","author":"Arai","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0370","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/bst0320387","article-title":"Phosphoinositide 3\u2010kinases and the regulation of platelet function","volume":"32","author":"Jackson","year":"2004","journal-title":"Biochem Soc Trans"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0375","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/38284","article-title":"Defective platelet activation in G alpha(q)\u2010deficient mice","volume":"389","author":"Offermanns","year":"1997","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0380","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1172\/JCI12818","article-title":"Impaired activation of murine platelets lacking G\u03b1i2","volume":"108","author":"Jantzen","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0385","doi-asserted-by":"crossref","first-page":"46035","DOI":"10.1074\/jbc.M208519200","article-title":"Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors","volume":"277","author":"Yang","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0390","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1083\/jcb.200112113","article-title":"Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton","volume":"157","author":"Obergfell","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0395","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.V93.8.2645","article-title":"Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets","volume":"93","author":"Law","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0400","doi-asserted-by":"crossref","first-page":"12056","DOI":"10.1073\/pnas.97.22.12056","article-title":"Hematopoietic reconstitution of SLP\u201076 corrects hemostasis and platelet signaling through alpha IIb beta 3 and collagen receptors","volume":"97","author":"Judd","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0405","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/01.CIR.0000028590.02477.6F","article-title":"Deposition of platelet RANTES triggering monocyte recruitment requires P\u2010selectin and is involved in neointima formation after arterial injury","volume":"106","author":"Schober","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0410","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nm810","article-title":"Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E","volume":"9","author":"Huo","year":"2003","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0415","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2002-07-2209","article-title":"Platelet P\u2010selectin facilitates atherosclerotic lesion development","volume":"101","author":"Burger","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0420","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0735-1097(98)00635-4","article-title":"Platelet activation in patients after an acute coronary syndrome: results from the TIMI\u201012 trial. Thrombolysis in myocardial infarction","volume":"33","author":"Ault","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0425","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/oxfordjournals.eurheartj.a015200","article-title":"Reduction of monocyte\u2010platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation","volume":"18","author":"May","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0430","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40 signalling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0435","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/15271","article-title":"Requirement for CD154 in the progression of atherosclerosis","volume":"5","author":"Lutgens","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0440","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa022600","article-title":"Soluble CD40 ligand in acute coronary syndromes","volume":"348","author":"Heeschen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0445","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjcard.2003.11.048","article-title":"Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention","volume":"93","author":"Quinn","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0450","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1084\/jem.20012044","article-title":"A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation","volume":"196","author":"Massberg","year":"2002","journal-title":"J Exp Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0455","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2010small\u2010cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0460","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/01.CIR.96.5.1488","article-title":"Effect of Ca2+ on GP IIb\u2010IIIa interactions with integrilin: enhanced GP IIb\u2010IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate","volume":"96","author":"Phillips","year":"1997","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2005.01418.x_bb0465","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1538-7836.2004.00907.x","article-title":"Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood","volume":"2","author":"Sakariassen","year":"2004","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2005.01418.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622163154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622163154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2005.01418.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:39:14Z","timestamp":1761532754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622163154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":92,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S1538783622163154"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01418.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches in arterial thrombosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01418.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}